Zacks: Establishment Labs Holdings Inc (ESTA) Receives Average Recommendation of “Strong Buy” from Analysts
Establishment Labs Holdings Inc (NASDAQ:ESTA) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $35.00 for the company and are predicting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Establishment Labs an industry rank of 69 out of 255 based on the ratings given to related companies.
A number of research firms have weighed in on ESTA. Zacks Investment Research downgraded shares of Establishment Labs from a “hold” rating to a “sell” rating in a research note on Monday, October 15th. Cowen assumed coverage on shares of Establishment Labs in a research note on Monday, August 13th. They issued an “outperform” rating and a $35.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Establishment Labs in a research note on Monday, August 13th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, BTIG Research assumed coverage on shares of Establishment Labs in a research note on Monday, August 13th. They issued a “buy” rating and a $35.00 target price on the stock.
Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, August 14th. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.15. The business had revenue of $13.71 million for the quarter, compared to analyst estimates of $12.10 million. Equities research analysts forecast that Establishment Labs will post -1.66 earnings per share for the current year.
Establishment Labs Company Profile
Establishment Labs Holdings Inc, a medical technology company, designs, develops, manufactures, and markets medical devices for aesthetic plastic surgery, reconstructive plastic surgery, and aesthetic dermatology. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name.
Featured Article: Diversification Important in Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.